



GEDEON RICHTER

Richter Acquires Discovery Portfolio of Celmatix

Budapest, 3 March 2026 – Gedeon Richter Plc. ("Richter") today announces the acquisition of the women's health discovery portfolio of Celmatix Inc., ("Celmatix") a US-based pioneering women's health biotech company dedicated to translating advances in female biology into novel therapeutics.

The assets acquired from Celmatix include a first-in-class oral Follicle-Stimulating Hormone (FSH) receptor agonist with the potential to transform fertility care by enabling more patient-friendly ovarian stimulation. The portfolio also features a novel Jun N-terminal kinase (JNK) inhibitor, which represents a potential non-hormonal immunotherapy approach for endometriosis aimed at addressing both pain and inflammation. In addition, the acquisition comprises early-stage therapeutic antibodies targeting anti-Müllerian hormone (AMH), including both agonists and antagonists, with the potential to provide unprecedented control over ovarian folliculogenesis.

This transaction further advances Richter's strategy to expand its innovative drug development capabilities across key women's health indications, including fertility, endometriosis and ovarian ageing. The development of the acquired programs will be led by the women's health original R&D hub of Richter in Belgium. The integration of these assets within the Belgian hub reinforces its role as the focal point for innovation in women's health, leveraging its scientific expertise within the framework of Richter's strategic priorities.

Under the asset purchase agreement, Celmatix will receive an upfront payment and will be eligible to receive development milestone payments as the drug pipeline advances into clinic and registration phase.

Dr. Péter Turek, Head of Women's Healthcare Business Unit at Richter, commented: *"For too long, women's health has been overlooked and despite medical progress, women are left with major unmet medical needs. By advancing research in key therapeutic areas of women's health such as endometriosis, ovarian ageing and infertility, we are strengthening our pipeline and broadening the scope of our scientific platform and innovation engine. This is fully in line with our ambition to become a thought leader in women's healthcare and to deliver innovative solutions that have the potential to meaningfully improve the lives of millions of women worldwide"*.

Dr. Piraye Yurttas Beim, Founder & CEO of Celmatix, added: *"Our mission has centered on three core realities of modern women's health. First, women need all their organs, including their ovaries, to function well throughout their lifespan. Second, chronic conditions such as endometriosis require disease-modifying, first-line treatments early in life to prevent downstream health consequences. And third, as women increasingly seek not just to survive but to thrive into their later years, they deserve access to more advanced fertility care. Expanding ovarian function across the lifespan, addressing endometriosis at its root rather than managing symptoms, and pioneering a paradigm shift in the therapeutic treatment of infertility have been foundational pillars of our work. It became clear to us that Gedeon Richter, with its long-standing legacy in women's health and its deep, sustained commitment to innovation, is the right home for these programs. Their scientific depth, global infrastructure, and multi-generational investment in this space give these assets the platform they ultimately need to reach patients. We are proud that this next chapter of the Celmatix portfolio will be written by a company that shares our vision and is prepared to advance it at global scale."*

[Chemical Works of Gedeon Richter Plc.](#)

Headquarters: H-1103 Budapest, Gyömrői út 19-21., Hungary • Postal address: H-1475 Budapest 10., Pf. 27., Hungary
Phone: +36 1 431 4000 • Fax: +36 1 260 6650, +36 1 260 4891 • Company Court of Budapest-Capital Tribunal Reg. No. Cg. 01-10-040944
EU Community VAT Identification No: HU 10484878 • Internet: www.gedeonrichter.com

About Richter

Richter aspires to be a global innovator in some key scientific fields, while dedicated to making medicines more accessible worldwide. Founded in 1901, headquartered in Hungary, with a market capitalization of EUR 4.8bn and sales of EUR 2.3bn in 2025, it operates Central Europe's largest R&D hub. Its research drives breakthroughs in Neuropsychiatry and Women's Healthcare, while Biotechnology and General Medicines strengthen its affordable treatment portfolio. Committed to sustainable growth, Richter invests in R&D, manufacturing excellence, and digitalization to advance medical innovation. Learn more at www.gedeonrichter.com

About Celmatix

Celmatix is a preclinical-stage women's health biotech focused on advancing groundbreaking therapeutics. Celmatix was founded in 2009 with the conviction that female biology is distinct and deserves to be studied, understood, and treated with the same scientific rigor applied to every other area of medicine. With its pipeline of innovative drug programs, Celmatix is addressing areas of high unmet need by developing the next generation of interventions and pioneering advancements in women's health. For more information, visit www.celmatix.com.

For further information:

Investors: Róbert Réthy, CFA
Media: Zsuzsa Beke

+36 20 342 2555
+36 20 916 4507

